Takeda Pharmaceutical Co ADR(TAK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:00 PM ET (Korea 10/24 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.34 | Insider Own | - | Shs Outstand | 3.18B | Perf Week | 2.9% |
| Market Cap | 64.41B | Forward P/E | 32.24 | EPS next Y | 60.32% | Insider Trans | - | Shs Float | 3.18B | Perf Month | 8.88% |
| Enterprise Value | 91.98B | PEG | 1.24 | EPS next Q | 0.14 | Inst Own | 3.29% | Short Float | 0.09% | Perf Quarter | 16.06% |
| Income | -1.05B | P/S | 2.15 | EPS this Y | 1.73% | Inst Trans | 0.22% | Short Ratio | 1.02 | Perf Half Y | 21.71% |
| Sales | 29.91B | P/B | 1.38 | EPS next 5Y | 25.97% | ROA | -1.08% | Short Interest | 2.92M | Perf YTD | 29.83% |
| Book/sh | 14.71 | P/C | 22.71 | EPS past 3/5Y | - | ROE | -2.22% | 52W High | -0.74% ($20.39) | Perf Year | 43.95% |
| Cash/sh | 0.89 | P/FCF | 14.77 | Sales past 3/5Y | 0.19% -0.17% | ROIC | -1.42% | 52W Low | 55.81% ($12.99) | Perf 3Y | 39.39% |
| Dividend Est. | $0.64 (3.18%) | EV/EBITDA | 9.93 | EPS Y/Y TTM | -208.74% | Gross Margin | 54.53% | Volatility(W/M) | 1.21% 1.38% | Perf 5Y | 43.85% |
| Dividend TTM | 0.63 | EV/Sales | 3.07 | Sales Y/Y TTM | -0.14% | Oper. Margin | 15.28% | ATR (14) | 0.34 | Perf 10Y | -11.34% |
| Dividend Ex-Date | 2026/3/31 | Quick Ratio | 0.62 | EPS Q/Q | -18.22% | Profit Margin | -3.49% | RSI (14) | 70.35 | Recom | 1.94 |
| Dividend Gr. 3/5Y | 1.18% -5.75% | Current Ratio | 1.14 | Sales Q/Q | - | SMA20 | 6.98% ($18.92) | Beta | 0.02 | Target Price | $20.8 |
| Payout | - | Debt/Eq | 0.65 | Earnings | 2026/7/30 | SMA50 | 8.85% ($18.59) | Rel Volume | 0.74 | Prev Close | $20.36 |
| Employees | 47029 | LT Debt/Eq | 0.58 | EPS/Sales Surpr. | 33.21% 7.4% | SMA200 | 16% ($17.45) | Avg Volume(3M) | 2.85M | Price | $20.24 |
| IPO | 2008/3/6 | Option/Short | Yes/Yes | Trades | 8066 | Volume | 2,099,266 | Change | -0.59% |
💊 Takeda Pharmaceutical is a global pharmaceutical company representing Japan, listed on the US NYSE in ADR form. It holds a broad therapeutic area portfolio that includes oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines, and is characterized by a multinational sales network and a stable operating structure based at its Japanese headquarters.
Over the past 1 year, on the higher side
1% below its 1-year high.
Traded less than usual. That is 74% of its average volume.
TAK keeps an operating profit but posts a net loss
Of every $100 in sales, $15.28 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +1.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $215. Peers typically go for $221.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +43.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 3.18% annually in dividends.
Tap to view numbers
Institutions barely hold it
Institutions hold 3.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It is the largest in the industry
Based on market cap of $64B.
TAK#1 Takeda Pharmaceutical Co ADR $64B PER - 
TEVA#2 Teva- Pharmaceutical Industries Ltd $46B PER 65.7 
HLN#3 Haleon plc ADR $45B PER 21.1 
ZTS#4 Zoetis Inc $33B PER 13.3 
UTHR#5 United Therapeutics Corp $25B PER 21.0 
FAQ
What kind of company is TAK?
TAK belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of TAK?
The market cap of TAK is approximately $64.4B, ranking 258 within its sector.
Does TAK pay dividends?
TAK has a dividend yield of approximately 3.18%, with an annual dividend of $0.64.
What is the 52-week high and low for TAK?
TAK has recorded a 52-week high of $20.39 and a low of $12.99.
